Abstract
SummaryImplementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-term remissions and reduced treatment-related toxicities for a substantial proportion of patients across several disease entities. Yet, adverse prognostic genetic aberrations such as TP53 dysfunctions and short-lived remissions after front-line therapy cannot be fully compensated with currently licensed novel agents thereby predisposing affected patients to inferior clinical outcomes in the long run. Moreover, acquired resistance and increasing drug intolerability typically evolving with continuous treatment remain challenges to overcome in daily clinical practice. With these unmet medical needs in mind, several clinical trials are currently investigating the efficacy and feasibility of time-limited novel drug combinations across several indolent B‑cell malignancies. This short review aims to give an update on novel clinical trial data presented at the International Conference of Malignant Lymphoma 2023.
Funder
University of Innsbruck and Medical University of Innsbruck
Publisher
Springer Science and Business Media LLC